Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[996]

Some of the highlights from the presentation at the China Rising Conference:

- net income (TTM) $ 27.0 million
- eps-basic (TTM) $ 2.59
- P/E 3.1x
- 17 approved TCM's waiting for launch
- strong cash position
- management focuses on share value
- government spending on healthcare is projected to increase 44% annually during the next 2 years
- continue to try to get more products included on provincial and national approved drug and prescription lists
- predicted revenue for fiscal year 2009 $ 111-116 million